CTNM insider transaction filings
Contineum Therapeutics, Inc. — 46 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-03. Screen CTNM transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-03 | 4 | Stengone Carmine N. — CEO and President, Director | Option exercise (M): 2,500 @ $1.01 · Sale (S): 2,500 @ $16.01 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Option exercise (M): 1,015 @ $1.01 · Sale (S): 1,015 @ $16 · Option exercise (M): 25 @ $1.01 · Sale (S): 25 @ $16 · Option exercise (M): 1,015 (derivative) @ $0 · Option exercise (M): 25 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Stengone Carmine N. — CEO and President, Director | Option exercise (M): 2,500 @ $1.01 · Sale (S): 2,500 @ $16 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Option exercise (M): 28,826 @ $1.01 · Sale (S): 28,826 @ $16.04 · Option exercise (M): 4,183 @ $1.01 · Sale (S): 5,852 @ $15.67 · Sale (S): 2,501 @ $16.24 · Option exercise (M): 28,826 (derivative) @ $0 · +1 more | EDGAR |
| 2026-07-01 | 4 | Watkins Tim — CMO & Head of Development | Option exercise (M): 10,833 @ $4.50 · Sale (S): 10,833 @ $16.02 · Option exercise (M): 10,833 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Stengone Carmine N. — CEO and President, Director | Option exercise (M): 7,500 @ $1.01 · Option exercise (M): 2,500 @ $1.26 · Sale (S): 10,000 @ $16.01 · Option exercise (M): 7,500 (derivative) @ $0 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Miralles Gines Diego — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Brady Todd R. — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Schimmelpennink Evert B. — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Lyons-Williams Lori — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Ware Olivia C — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Boyce Sarah — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Ignelzi Troy A. — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Sale (S): 4,170 @ $13.16 | EDGAR |
| 2026-05-01 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Sale (S): 3,870 @ $13.06 · Sale (S): 300 @ $13.84 | EDGAR |
| 2026-04-06 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Sale (S): 4,170 @ $13.43 | EDGAR |
| 2026-03-02 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Sale (S): 4,170 @ $15.01 | EDGAR |
| 2026-03-02 | 4 | Watkins Tim — CMO & Head of Development | Option exercise (M): 3,611 @ $4.50 · Sale (S): 3,611 @ $15.02 · Option exercise (M): 3,611 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Stengone Carmine N. — CEO and President, Director | Option exercise (M): 4,400 @ $1.26 · Sale (S): 4,400 @ $16.02 · Option exercise (M): 2,700 @ $1.26 · Sale (S): 2,700 @ $16.02 · Option exercise (M): 4,400 (derivative) @ $0 · Option exercise (M): 2,700 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Option exercise (M): 4,300 @ $1.01 · Sale (S): 4,300 @ $16.03 · Option exercise (M): 3,824 @ $1.01 · Sale (S): 3,824 @ $16.01 · Option exercise (M): 4,300 (derivative) @ $0 · Option exercise (M): 3,824 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Option exercise (M): 100 @ $1.01 · Sale (S): 100 @ $16 · Option exercise (M): 100 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Stengone Carmine N. — CEO and President, Director | Option exercise (M): 400 @ $1.26 · Sale (S): 400 @ $16 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Option exercise (M): 400 @ $1.01 · Sale (S): 400 @ $16 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Sale (S): 3,000 @ $14.82 · Sale (S): 1,170 @ $15.25 | EDGAR |
| 2026-01-30 | 4 | Healy John Stephen — General Counsel and Corp Sec | Grant/award (A): 206,411 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Stengone Carmine N. — CEO and President, Director | Grant/award (A): 445,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Grant/award (A): 160,000 (derivative) @ $0 · Grant/award (A): 6,500 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Watkins Tim — CMO & Head of Development | Option exercise (M): 3,611 @ $4.50 · Sale (S): 2,800 @ $14.09 · Sale (S): 811 @ $14.48 · Option exercise (M): 3,611 (derivative) @ $0 · Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Slover Peter T — Chief Financial Officer | Grant/award (A): 192,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Sale (S): 3,670 @ $10.35 · Sale (S): 500 @ $11.13 | EDGAR |
| 2025-12-30 | 4 | Watkins Tim — CMO & Head of Development | Option exercise (M): 3,611 @ $4.50 · Sale (S): 3,611 @ $12.06 · Option exercise (M): 3,611 (derivative) @ $0 | EDGAR |
| 2025-12-30 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Sale (S): 4,170 @ $12.23 | EDGAR |
| 2025-06-26 | 4 | Miralles Gines Diego — Director | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Brady Todd R. — Director | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Schimmelpennink Evert B. — Director | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Lyons-Williams Lori — Director | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Ware Olivia C — Director | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Boyce Sarah — Director | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Ignelzi Troy A. — Director | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-04-28 | 4 | Watkins Tim — CMO & Head of Development | Grant/award (A): 260,000 (derivative) @ $0 · Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Miralles Gines Diego — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Healy John Stephen — General Counsel and Corp Sec | Grant/award (A): 63,589 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Lorrain Daniel S. — Chief Scientific Officer | Grant/award (A): 110,000 (derivative) @ $0 · Grant/award (A): 3,700 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Huhn Stephen L. — CMO & Sr VP, Clinical Dev. | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Stengone Carmine N. — CEO and President, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Slover Peter T — Chief Financial Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Contineum Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CTNM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →